Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Oct 18 2021 Adamis Receives FDA Approval for ZIMHI
- Oct 4 2021 Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
- Sep 2 2021 Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
- Aug 24 2021 Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events